Idorsia Ltd.
http://www.idorsia.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Idorsia Ltd.
Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?
CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.
EMA Decision Time For Aztreonam-Avibactam; High-Stakes Meeting For Lecanamab
The European Medicines Agency is this week deciding whether a number of new drugs should win EU approval.
Idorsia Asset Sell Off Continues But Future Still Up In The Air
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.
Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023
With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice